

Click for [Full Prescribing Information](#) including **BOXED WARNING** if applicable.



Pfizer Inc.
275 North Field Drive
Lake Forest, IL 60045

September 17, 2021

Notification of Emergency Date Extension for Select Dextran 40 Presentations

Dear Customer,

Pfizer Hospital is committed to sharing timely product information so that U.S. customers can plan for patient care. The intent of this letter is to provide awareness that Pfizer Hospital has received approval¹ from the U.S. Food and Drug Administration (FDA) of our emergency request to extend the expiration date of three lots of select Dextran 40 presentations due to a current drug shortage.

Specifically, two lots of LMD 10% in 5% Dextrose Injection (dextran 40 in dextrose injection, USP) 500 mL Flexible Container, NDC 00409-7418-03, have been extended by 8 months, and one lot of LMD 10% in 0.9% Sodium Chloride Injection (dextran 40 in sodium chloride injection, USP) 500 mL Flexible Container, NDC 00409-7419-03, has been extended by 11 months.

Please review the lot numbers and emergency date extensions of the presentations listed below.

Unit of Sale NDC	Product Description	Lot(s)	Labeled Expiration Date	New Expiration Date
00409-7418-03	LMD 10% in 5% Dextrose Injection (dextran 40 in dextrose injection, USP) 500 mL Flexible Container	09141JT	01 Sep 2021	01 May 2022
		12090JT	01 Dec 2021	01 Aug 2022
00409-7419-03	LMD 10% in 0.9% Sodium Chloride Injection (dextran 40 in sodium chloride injection, USP) 500 mL Flexible Container	07011JT	01 Jul 2021	01 Jun 2022

The FDA is not requiring or recommending that the lots identified above be relabeled with new expiration dates. Please use available inventory on a first-in, first-out basis through the new expiration dates as noted above.

If you have any questions, please call our Customer Service Department at 1-844-646-4398.

Thank you,

Melissa Smetana
Senior Portfolio Manager, Premix and Micronutrients
Pfizer Hospital Business Unit U.S.

ⁱ Supplemental Abbreviated New Drug Applications (sANDA) BA 720563/67 and 720562/73, both approved by FDA on September 14, 2021.

© 2021 Pfizer Inc. All rights reserved. September 2021

